Q32 Bio Inc. — Director's Dealing 2018

Mar 27, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27

Reporting Person: PARMAR KUSH (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1330039	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (4204502)		Indirect
Series B Preferred Stock	$		Common Stock (1187535)		Indirect

Footnotes

F1: Includes 1,276,838 shares of common stock held by 5AM Ventures IV, L.P. ("Ventures IV") and 53,201 shares of common stock held by 5AM Co-Investors IV, L.P. ("Co-Investors IV").

F2: The preferred stock is convertible into the Issuer's common stock on a one-for-one basis at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F3: Includes 4,036,323 and 168,179 shares of Series A Preferred Stock held by Ventures IV and Co-Investors IV, respectively.

F4: Includes 1,140,034 and 47,501 shares of Series B Preferred Stock held by Ventures IV and Co-Investors IV, respectively.

F5: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F6: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.